Tejal Vishalpura, PharmD, joined Novo Nordisk, Inc. in March 2023 as Senior Vice President, Marketing, and was appointed Senior Vice President, Commercial Strategy & Marketing in January 2024. In this role, Tejal is responsible for leading the commercial strategy for Novo Nordisk’s innovative cardiometabolic therapy areas, to deliver transformative and human-centered experiences that put patient and customer needs first. Tejal is a transformational leader passionate about advancing capabilities of employees in support of discovering the potential of modern medicines so that Americans living with serious diseases have an opportunity to unlock their full human potential. 

Before joining Novo Nordisk, Tejal served as VP Global Head of Capabilities and Learning dedicated to building enterprise, medical, scientific, value and access capabilities, customer experience and integrated business planning. Prior to that, she was VP Global Head of Marketing and Launch Excellence where she was responsible for transforming launch capabilities across the Pharma division. While at Novartis, she also served as VP US Head of Immunology, Inflammatory Disease & Transplant Business Unit leading the business to sales growth.  She joined Novartis in 2018 as VP US Market Access National Accounts where she was also a member of the Executive Diversity Council.

Prior to Novartis, Tejal was at GlaxoSmithKline where she held multiple leadership roles of escalating responsibility including VP Pipeline Product Development, VP US Primary Care Sales, and Global Head of Digital Transformation.

She started her post-graduate career at Xcenda (Amerisource Bergen Specialty Group Consulting), providing corporate and brand strategy consulting services for Biotech companies.

Tejal has a Doctor of Pharmacy degree from The Ohio State University and is a recipient of the Healthcare Businesswomen’s Association National Rising Star Award.